![Robotic,Man,Cyborg,Face,Representing,Artificial,Intelligence,Concept,3d,Rendering Robotic man cyborg face representing artificial intelligence concept 3D rendering](https://www.modiblast.com/wp-content/uploads/elementor/thumbs/expert-says-shutterstock_1367031644-scaled-plfea2ajw2txawbphu4911ye3pt1cu5f7g1mjo1y0g.jpg)
What Experts say
What experts say
![image-2 image-2](https://www.modiblast.com/wp-content/uploads/elementor/thumbs/image-2-peukn09bbam6le7nppgjpwckt7szlug6xb6izy0su8.png)
“Modiblast is a very promising approach to address residual leukemic cells and convert them to ‘leukemia-derived DC’ that activate the patient’s immune system against blasts”
Prof. Dr. Hans-Jochem Kolb, the pioneer of stem cell transplantation in Germany
![EizVesper-removebg-preview EizVesper-removebg-preview](https://www.modiblast.com/wp-content/uploads/elementor/thumbs/EizVesper-removebg-preview-pjl1gl3y2t2uevhdi05jc3jai1qumtoo1ehtdpgp34.png)
“The Modiblast approach may entail substantial advantages compared to other therapies in the state-of-the-art”
Prof. Dr. Dr. Ulrike Köhl, Specialist for Cell Therapy and Immunobiology
![image-4 image-4](https://www.modiblast.com/wp-content/uploads/elementor/thumbs/image-4-peuko3qjac4850mbb6ivmmdxreeel4sx2qkx5ke9kw.png)
“We believe that in vivo therapy with response modifiers can become a promising treatment approach for leukemia patients”
Prof. Dr. A. Borkhard, Director Clinic f. Pediatric Oncology, Hematology, and Clinical Immunology, Düsseldorf